National Bank of Canada
NVIV

National Bank of Canada’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

National Bank of Canada’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20
Closed -$21 – 2893
2023
Q1 		$21 Buy
+20
New +$38 ﹤0.01% 2675

Other funds holding NVIV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

National Bank of Canada's NVIV Position: Q2 2023 in Review

National Bank of Canada sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2023, closing a stake of 20 shares — an estimated $21 sold.

National Bank of Canada first reported a position in NVIV in Q1 2023 and held it in 1 quarter. The position peaked at $21 in Q1 2023. 15 funds tracked by Wall St. Rank hold NVIV as of Q2 2023.

  • National Bank of Canada reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2023 after selling out during the quarter.
  • National Bank of Canada sold 20 InVivo Therapeutics Holdings Corp shares in Q2 2023, an estimated $21.
  • National Bank of Canada first reported a position in InVivo Therapeutics Holdings Corp in Q1 2023 and held it in 1 quarter.
  • National Bank of Canada's InVivo Therapeutics Holdings Corp position peaked at $21 in Q1 2023.
  • 15 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2023.

Based on National Bank of Canada's 13F filing for Q2 2023, filed 26 Jul 2023.